Notably, an analysis of two lung cancer patients who experienced a partial response to anti-PD-1 therapy but eventually progressed revealed upregulated expression of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) on TILs, to which anti-PD-1 antibodies were bound, at the time of resistance (85). This evidence concerns the gene HAVCR2 and lung carcinoma.